Cargando…
Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236369/ https://www.ncbi.nlm.nih.gov/pubmed/32477586 http://dx.doi.org/10.1186/s40814-020-00614-0 |
| _version_ | 1783536143095037952 |
|---|---|
| author | Legault, Kimberly Blostein, Mark Carrier, Marc Kahn, Susan Schulman, Sam Shivakumar, Sudeep Wu, Cynthia Crowther, Mark A. |
| author_facet | Legault, Kimberly Blostein, Mark Carrier, Marc Kahn, Susan Schulman, Sam Shivakumar, Sudeep Wu, Cynthia Crowther, Mark A. |
| author_sort | Legault, Kimberly |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7236369 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72363692020-05-29 Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome Legault, Kimberly Blostein, Mark Carrier, Marc Kahn, Susan Schulman, Sam Shivakumar, Sudeep Wu, Cynthia Crowther, Mark A. Pilot Feasibility Stud Correction BioMed Central 2020-05-18 /pmc/articles/PMC7236369/ /pubmed/32477586 http://dx.doi.org/10.1186/s40814-020-00614-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Legault, Kimberly Blostein, Mark Carrier, Marc Kahn, Susan Schulman, Sam Shivakumar, Sudeep Wu, Cynthia Crowther, Mark A. Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome |
| title | Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome |
| title_full | Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome |
| title_fullStr | Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome |
| title_full_unstemmed | Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome |
| title_short | Correction to: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome |
| title_sort | correction to: a single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236369/ https://www.ncbi.nlm.nih.gov/pubmed/32477586 http://dx.doi.org/10.1186/s40814-020-00614-0 |
| work_keys_str_mv | AT legaultkimberly correctiontoasinglearmfeasibilitycohortstudyofrivaroxabaninantiphospholipidsyndrome AT blosteinmark correctiontoasinglearmfeasibilitycohortstudyofrivaroxabaninantiphospholipidsyndrome AT carriermarc correctiontoasinglearmfeasibilitycohortstudyofrivaroxabaninantiphospholipidsyndrome AT kahnsusan correctiontoasinglearmfeasibilitycohortstudyofrivaroxabaninantiphospholipidsyndrome AT schulmansam correctiontoasinglearmfeasibilitycohortstudyofrivaroxabaninantiphospholipidsyndrome AT shivakumarsudeep correctiontoasinglearmfeasibilitycohortstudyofrivaroxabaninantiphospholipidsyndrome AT wucynthia correctiontoasinglearmfeasibilitycohortstudyofrivaroxabaninantiphospholipidsyndrome AT crowthermarka correctiontoasinglearmfeasibilitycohortstudyofrivaroxabaninantiphospholipidsyndrome |